Johnson & Johnson has agreed to acquire Intra-Cellular Therapies, a biopharmaceutical company specializing in treatments for central nervous system disorders. The acquisition, valued at approximately $14.6 billion, will involve a cash payment of $132.00 per share. This move will enhance Johnson & Johnson’s portfolio with Intra-Cellular Therapies’ CAPLYTA (lumateperone), an FDA-approved therapy for schizophrenia and bipolar depression, as well as a promising pipeline of compounds, including ITI-1284, under development for anxiety and Alzheimer’s-related conditions. The acquisition aligns with Johnson & Johnson's focus on advancing therapies for neuropsychiatric and neurodegenerative disorders, addressing the needs of millions worldwide.
CAPLYTA has demonstrated significant efficacy and safety across its approved indications and is undergoing further trials, including as an adjunctive therapy for major depressive disorder. The acquisition reflects Johnson & Johnson’s commitment to research and development, bolstered by Intra-Cellular Therapies’ expertise and established products. With more than a billion individuals globally affected by mental health and neurodegenerative conditions, Johnson & Johnson anticipates that this transaction will provide substantial benefits to patients and health systems. The company plans to fund the acquisition through cash and debt, maintaining its strategic focus on research investment and value-driven growth.
